Cancer drug developer ViraTherapeutics has been acquired by Boehringer Ingelheim, three years after the corporate led its series A round.
Pharmaceutical firm Boehringer Ingelheim acquired one of its portfolio companies, Austria-based immuno-oncology therapy developer ViraTherapeutics, yesterday for €210m ($245m).
ViraTherapeutics is developing oncological drugs based on oncolytic viruses that have been engineered to fight cancer, destroying cancerous cells while leaving surrounding tissue unharmed. It was spun out of Medical University of Innsbruck in 2013.
The company’s lead asset is a modified form of vesicular stomatitis virus called VSV-GP that enhances the patient’s immune response and impacts tumours directly. VSV-GP is…
